GlassScriptPhysician profile
Venkateswar Nandam
NPI 1669444626
$3,913.34
in general payments reported to CMS, 2019-2025
25 companies · $821 in 2025
The $821 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,337 · 2020: $466 · 2021: $81.03 · 2022: $315 · 2023: $371 · 2024: $521 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,694 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.68 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $778.56 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $703.25 | 2019-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $633.58 | 2022-2025 | |
| Glaxosmithkline, LLC. | $217.53 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $185.56 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Lilly USA, LLC | $167.75 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $155.67 | 2019-2023 | Delstrigo |
| Janssen Pharmaceuticals, INC | $139.85 | 2019 | |
| Pfizer INC. | $118.30 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $116.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $115.35 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.11 | 2019-2024 | Jardiance |
| Sunovion Pharmaceuticals INC. | $94.84 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $67.06 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $47.37 | 2025 | The Cologuard Plus Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $41.73 | 2019 | |
| Astellas Pharma US INC | $40.23 | 2019-2020 | |
| Shield Therapeutics INC | $37.13 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $30.50 | 2019-2023 | Livalo |
| Boston Scientific Corporation | $30.00 | 2025 | Watchman Flx |
| Phathom Pharmaceuticals, INC. | $23.15 | 2025 | Voquezna |
| Amarin Pharma, INC. | $22.99 | 2019 | |
| Medtronic, INC. | $15.29 | 2025 | Inceptiv |
| Verona Pharma, INC. | $15.27 | 2025 | Ohtuvayre |
| Allergan, INC. | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkateswar Nandam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.